<DOC>
	<DOCNO>NCT03055143</DOCNO>
	<brief_summary>This randomize , multi centre , open label , two treatment , two period , two sequence , single dose , crossover study , least 28 day washout dos , conduct fed ( normal breakfast ) condition .</brief_summary>
	<brief_title>Study Doxorubicin Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Availability volunteer entire study period willingness adhere protocol requirement evidence write informed consent . 2 . Patients metastatic breast cancer/advanced ovarian cancer age within range 1855 year . 3 . Subjects evidence underlie disease 4 . Subjects sign write consent form 1 . Females pregnant , breastfeeding , likely become pregnant 2 . Subjects medical condition ( except metastatic breast cancer/advanced ovarian cancer ) could jeopardize health prejudice result 3 . Subjects deem uncooperative noncompliant 4 . Smoking consumption nicotine product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>